Reuters logo
BRIEF-Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial
September 25, 2017 / 12:06 PM / in 3 months

BRIEF-Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial

Sept 25 (Reuters) - Catalyst Biosciences Inc

* Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial

* Catalyst Biosciences Inc - ‍companies plan to have interim top-line data from trial by end of 2017​

* Catalyst Biosciences- ‍announced collaborator Isu Abxis completed dosing of first subcutaneous cohort in ongoing Phase 1/2 proof-of-concept clinical trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below